Retatrutide + Semaglutide

Phase 3Active
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Feb 21, 2024 โ†’ Jan 1, 2027

About Retatrutide + Semaglutide

Retatrutide + Semaglutide is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is active. This product is registered under clinical trial identifier NCT06260722. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06260722Phase 3Active